非酒精性脂肪性肝病、非酒精性脂肪性肝炎及相关纤维化的诊断方法
非酒精性脂肪性肝病(NAFLD)全球患病率约25%,包括单纯性脂肪变、非酒精性脂肪性肝炎(NASH)、进展性纤维化和肝硬化。肝活检是诊断和分期NASH最准确的方法,但存在有创、昂贵、并发症和观察者间变异等问题。多种无创诊断方法正在开发中,其曲线下面积多在0.76至0.90%之间,磁共振弹性成像(MRE)预测性能最佳。
要点
- NAFLD全球患病率约25%,亚洲呈现城市高于农村的梯度。
- 肝活检是诊断和分期NASH最准确的方法,但存在有创、昂贵、并发症及观察者间变异。
- 无创诊断方法曲线下面积多在0.76至0.90%之间,MRE预测性能最佳。
核心结论
- 开发安全、易获取的无创诊断方法以准确诊断和监测NASH及相关纤维化,在临床实践和临床研究中至关重要。
- 这些检测不仅有助于对进展性肝病风险最高的受试者进行风险分层,还可作为NASH治疗临床试验的适当替代终点。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- NAFLD全球患病率约25%,亚洲呈现从城市到农村由高到低的患病率梯度。
- 肝活检是诊断和分期NASH最准确的方法,但存在有创、昂贵、并发症及观察者间变异等问题。
- 无创诊断方法包括预测模型(NAFLD纤维化评分)和血清生物标志物如增强肝纤维化(ELF)。
- 基于影像学技术的检测如瞬时弹性成像(TE)或磁共振弹性成像(MRE)用于估计肝硬度作为肝纤维化的潜在替代指标。
- 大多数无创诊断方法的曲线下面积在0.76至0.90%之间,MRE预测性能最佳。
关键数值与推荐
- NAFLD全球患病率约25%。
- 大多数无创诊断方法的曲线下面积在0.76至0.90%之间,MRE预测性能最佳。
临床怎么用
- 原文未据此给出推荐。
局限性
- 肝活检虽为最准确方法,但有创、昂贵、与潜在并发症相关,且受个体病理特征观察者间变异困扰。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis, nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. The majority of NAFLD subjects do not have NASH and do not carry a significant risk for liver-related adverse outcomes (cirrhosis and mortality). Globally, the prevalence of NAFLD is approximately 25%. In Asia, a gradient of high to low prevalence rates is noted from urban to rural areas. Given the prevalence of NAFLD, the clinical and economic burden of NAFLD and NASH can be substantial. With increasing recognition of NASH as an important liver disease, the diagnosis of NASH still requires a liver biopsy that is suboptimal. Although liver biopsy is the most accurate modality to diagnose and stage the severity of NASH, this method suffers from being invasive, costly, associated with potential complications, and plagued with interobserver variability of individual pathological features. A number of noninvasive modalities to diagnose NASH and stage liver fibrosis are being developed. These modalities include predictive models (NAFLD fibrosis score) and serum biomarkers such as enhanced liver fibrosis (ELF). Other tests are based on radiological techniques, such as transient elastography (TE) or magnetic resonance elastography (MRE), which are used to estimate liver stiffness as a potential surrogate of hepatic fibrosis. Although a dynamic field of research, most of these diagnostic modalities have area under the curve ranging between 0.76 and 0.90%, with MRE having the best predictive performance. In summary, developing safe and easily accessible noninvasive modalities to accurately diagnose and monitor NASH and associated fibrosis is of utmost importance in clinical practice and clinical research. These tests are not only important to risk stratify subjects at the greatest risk for progressive liver disease, but also to serve as appropriate surrogate endpoints for therapeutic clinical trials of NASH. (Hepatology 2018;68:349-360).
引用
- Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018. PMID: 29222917. doi:10.1002/hep.29721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。